COMPOSITIONS AND METHODS FOR TREATMENT OF MALIGNANT TUMOUR Russian patent published in 2018 - IPC A61K38/43 A61P35/00 

Abstract RU 2660349 C2

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and can be used to treat a patient with a malignant tumour associated with a WEE1 kinase. To this end, the patient undergoes measurement of the expression level of the PKMYT1 gene in a biological sample containing malignant cells obtained from said patient and in a control sample. Further, it is determined whether expression level of the PKMYT1 gene in said sample from the patient is higher or lower than the expression level in said control sample. Said patient is then selected for treatment with a WEE1 inhibitor if the PKMYT1 level from the patient’s sample is lower than in the control sample. And the patient selected for treatment of a malignant tumour is injected with a WEE1 inhibitor. Also disclosed is a method for treating a patient with a malignant tumour associated with a WEE1 kinase, where the patients are characterised by low expression levels of PKMYT1.

EFFECT: group of inventions provides treatment of a malignant tumour in patients with low expression levels of PKMYT1.

13 cl, 20 dwg, 9 ex

Similar patents RU2660349C2

Title Year Author Number
THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR BLADDER CANCER 2015
  • Choi, Younjeong
  • Kabbarah, Omar
  • Kim, Doris
RU2739942C2
BIOMARKERS PREDICTING A THERAPEUTIC RESPONSE TO THERAPY WITH A CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF 2015
  • Bedoya Felipe
  • Bitter Hans
  • Brogdon Jennifer
  • Dorfmeier Corin
  • Garg Abhishek
  • Glass David
  • Mannick Joan
  • Melenhorst Jan J.
  • Milone Michael C.
  • Murphy Leon
  • Orlando Elena
  • Wilcox Nicholas
RU2743657C2
DIAGNOSTIC MARKERS 2012
  • Shejms Devid
  • Dzhanuario Tomas E.
RU2614254C2
METHODS FOR TREATMENT OF MALIGNANT TUMORS, USING ATR INHIBITOR 2018
  • Penney, Marina
  • Pollard, John Robert
  • Takemoto, Darin
  • Geho, David
  • Sullivan, James
  • Reaper, Philip Michael
RU2813966C2
TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR 2015
  • Brogdon, Jennifer
  • Byrd, John
  • Dubovsky, Jason
  • Fraietta, Joseph
  • Gill, Saar
  • Glass, David
  • Johnson, Amy
  • June, Carl, H.
  • Kenderian, Saad
  • Mannick, Joan
  • Maus, Marcela
  • Murphy, Leon
  • Muthusamy, Natarajan
  • Porter, David L.
  • Ruella, Marco
  • Sellers, William Raj
  • Wasik, Mariusz
RU2718542C2
MARKERS ASSOCIATED WITH WNT INHIBITORS 2014
  • Che, Tszyanvej
  • Kharris, Dzhennifer
  • Khsiekh, Khsin-I
  • Li, Tsze
  • Lyu, Tszyun
  • Ng, Nikolas
RU2663701C2
BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS 2014
  • Chen, Deniel Shin-Yuj
  • Khedzh, Priti
  • Koeppen, Khartmut
  • Kovanetz, Marsin
RU2820869C1
BIOMARKERS AND METHODS OF TREATING ASSOCIATED WITH PD-1 AND PD-L1 CONDITIONS 2014
  • Chen Daniel Shin-Yu
  • Hegde Priti
  • Koeppen Hartmut
  • Kowanetz Marcin
RU2701378C2
COMBINATION OF CHEKPOINT-KINASE 1 INHIBITORS AND WEE 1 KINASE INHIBITORS 2011
  • Dejvis Kertis D.
  • Gros Stefan
RU2627841C2
METHOD OF USING AXL AS MARKER OF EPITHELIAL-MESENCHYMAL TRANSITION 2010
  • Lorens Dzhejms Bredli
  • Miklem Devid Robert
  • Akslen Lars
RU2586493C2

RU 2 660 349 C2

Authors

Shamvej Styuart Denkhem

Dates

2018-07-05Published

2013-11-22Filed